Indomethacin and Alzheimer's Disease Progression
Author Information
Author(s): de Jong Daniëlle, Jansen René, Hoefnagels Willibrord, Jellesma-Eggenkamp Marja, Verbeek Marcel, Borm George, Kremer Berry
Primary Institution: Radboud University Nijmegen Medical Center
Hypothesis
Indomethacin may retard the clinical progression of Alzheimer's disease.
Conclusion
The study found that indomethacin did not significantly slow the progression of Alzheimer's disease.
Supporting Evidence
- The deterioration on the ADAS-cog was less in the indomethacin group than in the placebo group.
- The study was discontinued prematurely due to recruitment difficulties.
- No significant differences were found in secondary outcome measures.
Takeaway
The study tested if a medicine called indomethacin could help people with Alzheimer's disease, but it didn't work as hoped.
Methodology
This was a double-blind, randomized, placebo-controlled trial with 51 patients receiving either indomethacin or placebo for one year.
Potential Biases
The study population was highly selected, which may not represent the average Alzheimer's disease population.
Limitations
The study was underpowered due to recruitment difficulties and had strict exclusion criteria, limiting generalizability.
Participant Demographics
Patients had mild to moderate Alzheimer's disease, with a mean age of approximately 72 years.
Statistical Information
Confidence Interval
−4.5–7.5
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website